Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Exelixis (EXEL) stocks in Canada

Learn how to easily invest in Exelixis stocks.

Exelixis (EXEL) is a leading biotechnology business based in the US. It opened the day at $18.03 after a previous close of $17.83. During the day the price has varied from a low of $17.87 to a high of $18.32. The latest price was $18.01 (25 minute delay). Exelixis is listed on the NASDAQ and employs 773 staff. All prices are listed in US Dollars.

How to buy shares in Exelixis

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EXEL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Exelixis stock price (NASDAQ:EXEL)

Use our graph to track the performance of EXEL stocks over time.

Exelixis shares at a glance

Information last updated 2021-07-09.
Previous close$17.83
Change $0.18
Change % 1.0095%
Volume 1,306,706
Information last updated 2022-01-24.
52-week range$15.50 - $25.77
50-day moving average $17.75
200-day moving average $20.09
Wall St. target price$29.62
PE ratio 36.3137
Dividend yield N/A (0%)
Earnings per share (TTM) $0.51

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Exelixis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Exelixis price performance over time

Historical closes compared with the close of $18.01 from 2022-01-27

1 week (2022-01-17) N/A
1 month (2021-12-24) N/A
3 months (2021-10-28) -17.23%
6 months (2021-07-28) 5.08%
1 year (2021-01-28) -19.24%
2 years (2020-01-28) 0.73%
3 years (2019-01-28) 23.07
5 years (2017-01-27) 18.57

Is Exelixis under- or over-valued?

Valuing Exelixis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exelixis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Exelixis's P/E ratio

Exelixis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, Exelixis shares trade at around 36x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Exelixis's PEG ratio

Exelixis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4166. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exelixis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Exelixis's EBITDA

Exelixis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $211.1 million.

The EBITDA is a measure of a Exelixis's overall financial performance and is widely used to measure a its profitability.

Exelixis financials

Revenue TTM $1.3 billion
Operating margin TTM 15.71%
Gross profit TTM $954 million
Return on assets TTM 5.4%
Return on equity TTM 8.29%
Profit margin 13.1%
Book value $6.68
Market capitalisation $5.9 billion

TTM: trailing 12 months

Exelixis share dividends

We're not expecting Exelixis to pay a dividend over the next 12 months.

Exelixis share price volatility

Over the last 12 months, Exelixis's shares have ranged in value from as little as $15.5 up to $25.77. A popular way to gauge a stock's volatility is its "beta".

EXEL.US volatility(beta: 0.88)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exelixis's is 0.8794. This would suggest that Exelixis's shares are less volatile than average (for this exchange).

Exelixis overview

Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer.

Stocks similar to Exelixis

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

Go to site